103 related articles for article (PubMed ID: 9422083)
41. Antimetastatic effect of amiloride in an animal tumour model.
Kellen JA; Mirakian A; Kolin A
Anticancer Res; 1988; 8(6):1373-6. PubMed ID: 3218971
[TBL] [Abstract][Full Text] [Related]
42. Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors.
Bhatti RA; Gadarowski JJ; Ray PS
Tumour Biol; 1997; 18(1):1-5. PubMed ID: 8989919
[TBL] [Abstract][Full Text] [Related]
43. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Anticancer Res; 2007; 27(6B):3843-8. PubMed ID: 18225541
[TBL] [Abstract][Full Text] [Related]
44. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
45. Effect of urokinase type plasminogen activator on
Roldán-Olarte M; Maillo V; Sánchez-Calabuig MJ; Beltrán-Breña P; Rizos D; Gutiérrez-Adán A
Reproduction; 2017 Sep; 154(3):231-240. PubMed ID: 28667127
[TBL] [Abstract][Full Text] [Related]
46. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
47. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
48. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Pulukuri SM; Estes N; Patel J; Rao JS
Cancer Res; 2007 Feb; 67(3):930-9. PubMed ID: 17283123
[TBL] [Abstract][Full Text] [Related]
49. Prevention of metastasis by inhibition of the urokinase receptor.
Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
[TBL] [Abstract][Full Text] [Related]
50. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
51. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
52. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Demetriou MC; Pennington ME; Nagle RB; Cress AE
Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
[TBL] [Abstract][Full Text] [Related]
53. Secretion of plasminogen activator from bovine parathyroid cells.
Bansal DD; MacGregor RR
Endocrinology; 1990 May; 126(5):2245-51. PubMed ID: 2109681
[TBL] [Abstract][Full Text] [Related]
54. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Helenius MA; Savinainen KJ; Bova GS; Visakorpi T
BJU Int; 2006 Feb; 97(2):404-9. PubMed ID: 16430655
[TBL] [Abstract][Full Text] [Related]
55. Regulation of plasminogen activator in rat endometrial stromal cells: the role of prostaglandin E2.
Zhang X; Shu MA; Ross HE; Kennedy TG
Biol Reprod; 1996 May; 54(5):1046-51. PubMed ID: 8722625
[TBL] [Abstract][Full Text] [Related]
56. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
57. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
58. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Dong-Le Bourhis X; Lambrecht V; Boilly B
Br J Cancer; 1998; 77(3):396-403. PubMed ID: 9472634
[TBL] [Abstract][Full Text] [Related]
59. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
60. Urokinase-type plasminogen activator expression in human prostate carcinomas.
Van Veldhuizen PJ; Sadasivan R; Cherian R; Wyatt A
Am J Med Sci; 1996 Jul; 312(1):8-11. PubMed ID: 8686732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]